Takeda Pharmaceutical announced the launch of LIOVEL®, a fixed dose combination tablet of NESINA® (alogliptin) and ACTOS® (pioglitazone HCl) for treatment of type 2 diabetes.
LIOVEL is a tablet taken orally once daily and has two dosage strengths, “LIOVEL LD” and “LIOVEL HD” which contain 25mg alogliptin /15mg pioglitazone, and 25mg alogliptin /30mg pioglitazone respectively.
NESINA was discovered by Takeda’s wholly-owned subsidiary, Takeda San Diego, Inc. and is a member of the Dipeptidyl Peptidase-4 (DPP-4) inhibitors class. It increases insulin secretion and lowers blood glucose level by inhibiting DPP-4 which is an enzyme inactivating two hormones, GLP-1 and GLP, selectively. ACTOS is a thiazolidinedione (TZD) class and lowers blood glucose level by improving insulin resistance.
The information regarding potential bladder cancer risk mentioned in the Japanese ACTOS package insert is reflected into the LIOVEL package insert.